Massachusetts is the latest state to file suit against Johnson & Johnson’s Ortho-McNeil-Janssen unit over the marketing of its anti-psychotic drug Risperdal, according to a news release from Attorney General Martha Coakley.
The suit alleges that Janssen promoted the drug to treat elderly dementia and other conditions when these uses had not been proven safe and effective, nor approved by the U.S. Food and Drug Administration. The complaint also claims Janssen did not properly disclose the serious risks associated with the drug's use, including an increased risk of death.
Read the news release from Attorney General Martha Coakley on Massachusetts' lawsuit against Johnson & Johnson over Risperdal.
The suit alleges that Janssen promoted the drug to treat elderly dementia and other conditions when these uses had not been proven safe and effective, nor approved by the U.S. Food and Drug Administration. The complaint also claims Janssen did not properly disclose the serious risks associated with the drug's use, including an increased risk of death.
Read the news release from Attorney General Martha Coakley on Massachusetts' lawsuit against Johnson & Johnson over Risperdal.
Related Articles on Lawsuits Between States and Pharmaceutical Companies:
Kentucky AG Sues McKesson Over Alleged 10-Year Overpricing Scheme
Arkansas to Bring AstraZeneca to Trial in 2012 For Alleged Off-Label Marketing
Michigan Accuses McKesson of Inflating Drug Prices, Overbilling Medicaid